Table 5a.
Univariate analysis of age and immune phenotype on clinical outcomes, p values < 0.100 in bold.
| Effect | MELD-XI | SOFA | Time to infection | BTT* | Time to death | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Diff. (95% CI) | p | Diff. (95% CI) | p | HR (95% CI) | p | OR (95% CI) | p | HR (95% CI) | p | |
| Age (yrs) | 0.17 (0.06, 0.29) | 0.004 | 0.09 (0.01, 0.17) | 0.030 | 1.00 (0.97, 1.04) | 0.857 | 0.91 (0.83, 1.00) | 0.061 | 1.01 (0.97, 1.05) | 0.635 |
| CM CD4 +§ | 0.11 (−0.01, 0.23) | 0.063 | 0.04 (−0.05, 0.14) | 0.372 | 1.00 (0.94, 1.06) | 0.966 | 0.91 (0.81, 1.02) | 0.096 | 1.06 (0.99, 1.13) | 0.096 |
| EM CD4 +§ | 0.01 (−0.06, 0.09) | 0.762 | 0.03 (−0.03, 0.08) | 0.392 | 1.02 (0.99, 1.05) | 0.298 | 0.97 (0.91, 1.04) | 0.366 | 1.02 (0.99, 1.05) | 0.244 |
| TMRA CD4 +§ | 0.25 (−0.05, 0.55) | 0.098 | 0.04 (−0.20, 0.28) | 0.743 | 1.09 (0.98, 1.22) | 0.129 | 0.99 (0.79, 1.24) | 0.917 | 0.93 (0.78, 1.12) | 0.466 |
| CM CD8 +¶ | 0.43 (0.07, 0.79) | 0.020 | 0.32 (0.03, 0.61) | 0.033 | 1.03 (0.69, 1.55) | 0.878 | 0.71 (0.45, 1.12) | 0.138 | 1.15 (0.89, 1.49) | 0.292 |
| EM CD8 +¶ | 0.09 (0.01, 0.17) | 0.023 | 0.03 (−0.03, 0.09) | 0.368 | 1.00 (0.96, 1.03) | 0.872 | 1.03 (0.94, 1.12) | 0.565 | 1.01 (0.98, 1.05) | 0.485 |
| TMRA CD8 +¶ | 0.07 (0.00, 0.14) | 0.038 | 0.06 (0.01, 0.11) | 0.030 | 1.03 (1.00, 1.05) | 0.060 | 0.94 (0.88, 1.00) | 0.070 | 1.01 (0.98, 1.04) | 0.564 |
| CD4+ PD1 + CD57 + | −0.04 (−0.15, 0.07) | 0.506 | −0.05 (−0.14, 0.04) | 0.252 | 1.06 (1.01, 1.11) | 0.026 | 0.97 (0.86, 1.08) | 0.565 | 1.00 (0.95, 1.06) | 0.969 |
| CD8+ PD1 + CD57 + | 0.05 (−0.09, 0.19) | 0.486 | −0.02 (−0.13, 0.08) | 0.656 | 1.01 (0.97, 1.05) | 0.593 | 0.94 (0.86, 1.04) | 0.222 | 1.02 (0.98, 1.07) | 0.331 |
| CD8+ CD28− | 0.04 (0.00, 0.08) | 0.077 | 0.04 (0.00, 0.07) | 0.045 | 1.00 (0.98, 1.02) | 0.825 | 1.00 (0.95, 1.05) | 0.937 | 1.01 (0.98, 1.03) | 0.630 |
| CD8+ KLRG1 + | 0.02 (−0.03, 0.08) | 0.404 | 0.00 (−0.04, 0.04) | 0.958 | 1.00 (0.98, 1.02) | 0.797 | 0.99 (0.95, 1.03) | 0.598 | 1.00 (0.98, 1.03) | 0.667 |
| CD8+ KRLG1+CD28− | 0.06 (−0.03, 0.15) | 0.211 | 0.02 (−0.04, 0.09) | 0.474 | 0.99 (0.97, 1.02) | 0.565 | 1.01 (0.96, 1.06) | 0.738 | 1.00 (0.98, 1.03) | 0.998 |
| CD4+ CD38 + | 0.06 (−0.02, 0.15) | 0.151 | 0.05 (−0.01, 0.12) | 0.129 | 0.98 (0.94, 1.02) | 0.309 | 1.03 (0.96, 1.11) | 0.377 | 0.95 (0.91, 0.99) | 0.026 |
| CD8+ CD38 + | −0.02 (−0.08, 0.05) | 0.614 | −0.01 (−0.06, 0.03) | 0.589 | 1.00 (0.98, 1.02) | 0.869 | 1.00 (0.96, 1.05) | 0.988 | 0.99 (0.96, 1.01) | 0.373 |
| NKT+ KLRG1 + | 0.04 (−0.02, 0.09) | 0.235 | 0.04 (0.01, 0.08) | 0.022 | 0.99 (0.97, 1.01) | 0.285 | 0.96 (0.91, 1.01) | 0.128 | 1.03 (1.01, 1.06) | 0.012 |
Diff.: Difference; CM, Central Memory; EM, Effector Memory, TMRA, Terminally differentiated RA+.
*
BTT: Bridge to Transplant, excluding 4 patients with MCS implant as destination therapy.
§
Compared to CD4+ CCR7+RA+ reference group.
¶
Compared to CD8+ CCR7+RA+ reference group.